The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.
Joined July 2010
- Tweets 3,205
- Following 320
- Followers 25,672
- Likes 755
1,514 Photos and videos
Pinned Tweet
May 18
Submit to our special series on Clinical Cancer Epidemiology & Real-World Evidence to help advance oncology care across prevention, diagnosis, treatment, and survivorship.
👉Learn more and submit your research:
academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
1
1
402
Jun 11
Belzutifan earning its place across the RCC continuum. Post-IO/TKI approval, now 2L w/ lenva PFS 14.8 v 10.7 m (HR 0.70) v cabo, & adjuvant DFS HR 0.72 w/ pembro. OS data will tell the full story. 🧬 #RCC
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
1
2
445
This study shows #timetox in #pancsm with 20–40% of life spent in healthcare contact after surgery prior to death #GIonc #pallonc #supponc
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
2
3
281
We’re seeking research using real-world data to improve cancer outcomes.
Topics include early detection, treatment effectiveness, and survivorship.
🔬Learn more and submit by Oct 31, 2026: academic.oup.com/oncolo/page…
#CancerResearch #Epidemiology
296
This commentary explores #timetox for Phase II cancer trial participants, who spend ~2 days/month in #research care. This time burden consumes 4–10% of survival time #pallonc #supponc
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
1
3
327
The Oncologist retweeted
Thrilled to share our REGETNE-Thyroid Registry real-world data on ATC — one of the largest European cohorts to date.
Molecular testing, IO, TKIs & local surgery improved OS.
Huge thanks to all co-authors & participating centers!
#ATC #ThyroidCancer
academic.oup.com/oncolo/adva…
2
6
784
The Oncologist retweeted
May 26
Excited to share our new paper on patient-reported time toxicity with bispecific antibodies (mosun, glofi, epco) in R/R FL and DLBCL @OncJournal.
A few key points from our study, including impacts on time tox research & patient-centered #lymsm care: 🧵
academic.oup.com/oncolo/adva…
1
10
46
6,106
May 26
Temozolomide reconsidered: Real-world evidence in resistant melanoma cases
#MelanomaAwareness
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
1
267
May 22
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
3
4
317
May 19
An interview with Dr. Francesco Schettini, winner of The Oncologist 2024 Early Career Investigator Award:
academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
1
3
357
May 14
Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
2
2
456
May 11
Letter to the Editor: Tumor growth rate as an intermediate trial endpoint: doi.org/10.1093/oncolo/oyag1…
RE: doi.org/10.1093/oncolo/oyag0…
@susanebates @gbanna74 @PasRescigno
2
2
461
2
3
314
Real-world data showing that patients with refractory solid tumors receiving treatment matched to MTB recommendations had ⬆️OS and PFS, supporting the clinical impact of precision MTB-guided therapy.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyaf1…
5
3
503
ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyaf3…
2
1
306
Can patients, their informal care partners, & their oncologists recall health care contact days over past 1-2 weeks? Yes, fairly accurately! More work needed to develop this simple contact days recall PRO.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag0…
1
1
1
191
Apr 30
What is the 2L best option after Gem-NabP for patients with metastatic PDAC? Study shows how Interpretable AI outperforms uniform strategies, patient subgroups that truly benefit from Nal-IRI.
#PancreaticCancer #AI
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag0…
2
2
343
Apr 28
S-1 vs UFT in rectal cancer
âś…S-1 improves RFS
âś…Net Treatment Benefit provides a nuanced view on benefit-risk balance
⚠️Age matters: benefit <70 yr, no sig diff ≥70 yr
➡️Pt-centric benefit-risk assessment matters! @susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag0…
1
2
4,911
Apr 27
This real-life study provides additional insight into the use of anti-EGFR and anti-PD1 combination therapy in a later-line setting. #skincancer #immunotherapy #cSCC #reallife
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag0…
2
1
369
Apr 24
Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyaf4…
3
7
430